SFI
TPST icon

Susquehanna Fundamental Investments’s Tempest Therapeutics TPST Stock Holding History

Susquehanna Fundamental Investments’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-112
Closed -$36K – 1608
2020
Q3 		$36K Hold
112
– – ﹤0.01% 1334
2020
Q2 		$39K Buy
+112
New +$44.7K ﹤0.01% 949

Other funds holding TPST

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Susquehanna Fundamental Investments's TPST Position: Q4 2020 in Review

Susquehanna Fundamental Investments sold out of Tempest Therapeutics (TPST) in Q4 2020, closing a stake of 112 shares — an estimated $36K sold.

Susquehanna Fundamental Investments first reported a position in TPST in Q2 2020 and held it in 2 quarters. The position peaked at $39K in Q2 2020. 37 funds tracked by Wall St. Rank hold TPST as of Q4 2020.

  • Susquehanna Fundamental Investments reported no remaining Tempest Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 112 Tempest Therapeutics shares in Q4 2020, an estimated $36K.
  • Susquehanna Fundamental Investments first reported a position in Tempest Therapeutics in Q2 2020 and held it in 2 quarters.
  • Susquehanna Fundamental Investments's Tempest Therapeutics position peaked at $39K in Q2 2020.
  • 37 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q4 2020.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2020, filed 16 Feb 2021.